http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Gwang Hyeon Choi ),( Eun Sun Jang ),( Young Seok Kim ),( Youn Jae Lee ),( In Hee Kim ),( Sung Bum Cho ),( Han Chu Lee ),( Jang Jeong Won ),( Moran Ki ),( Hwa Young Choi ),( Dahye Baik ),( Sook-hyang 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: This study aimed to elucidate the all-cause mortality and the incidence hepatocellular carcinoma (HCC), and their related factors among the patients with chronic hepatitis C virus (HCV) infection in South Korea. Methods: A total 2,369 patients with HCV RNA positivity and no HCC at diagnosis (mean age 57.5 years, 47.6% male, 29.8% cirrhosis) were prospectively enrolled in 6 university hospitals from May 2007 to March 2019 and followed until February 2020. The patients were classified into untreated group (n=753, 31.8%), interferon (IFN)-based treated group (n=698, 29.5%), and direct-acting antivirals (DAA)-treated group (n=918, 38.8%). Kaplan-Meier curve analysis and Cox regression analysis were performed. Results: During 4.3 years (IQR 2.5-7.6) of median follow-up, 245 patients died and 147 developed HCC. The 3-, 5-, and 10-year cumulative mortality in the HCV patients was 4.6%, 8.0%, and 12.8%, respectively. The 3-, 5-, and 10-year cumulative incidence of HCC was 4.5%, 8.5%, and 18.3%, respectively. The SVR rate was 68.7% in IFN-based treated group and 95.2% in DAA-treated group, by per-protocol analysis. After multivariate analysis, achievement of SVR was an independent factor for decreased risk of HCC (adjusted hazard ratio [aHR] 0.22, 95% confidence interval [CI] 0.12-0.39, P<0.001 for IFN based-treated group and aHR 0.29, 95% CI 0.17-0.50, P<0.001 for DAA-treated group, respectively). SVR was an independent factor for decreased risk of all cause of mortality (aHR 0.27, 95% CI 0.17-0.44, P<0.001 for IFN based-treated group and aHR 0.23, 95% CI 0.12-0.45, P<0.001 for DAA-treated group, respectively) along with other factors. Conclusions: In Korea HCV cohort, 5-year cumulative incidence of HCC and mortality was 8.0% and 8.5%, respectively. The overall treatment rate was 70% with overall SVR rate of 86%. Achievement of SVR was a strong factor for better outcomes, which support active screening and treatment of HCV infection.
이윤국 ( Youn Goog Lee ),윤상훈 ( Sang Hoon Yoon ),조광운 ( Gwang Woon Jo ),위환 ( Whan Wi ),김난희 ( Nan Hee Kim ),강영주 ( Yeong Ju Kang ),김은선 ( Eun Sun Kim ),서광엽 ( Gwang Yeob Seo ) 한국환경분석학회 2013 환경분석과 독성보건 Vol.16 No.2
This study was performed to investigate the water quality of non-designated spring in Gwangju. Samples were collected at 9 sites from April 2012 to March 2013. The average concentrations of physicochemical items at each sites satisfied with drinking water guideline except microorganisms. The concentrations of main minerals including Ca2+, Mg2+, K+ and Na+ showed generally similar and higher than those of bottled minerals water in some sites. Total coliforms and fecal coliforms were detected in some sample collected except S1 and S4 site. The microorganisms isolated in the natural mineral water found out E. coli (62%), Raoultella planticola (10%), Citrobacter freundii (9%) and so on. Detection of these microorganisms showed that the environment around the spring had been exposed to fecal contamination. For the efficient control, the government office needs to designate the S1 and S4 site found out the acceptance for drinking water standard as the management spring water.
블루투스 Piconet을 이용한 임베디드 시스템 원격 제어
장윤석(Youn-seok Jang),정경호(Kyung-ho Jung),안광선(Gwang-sun Ahn) 한국정보과학회 2004 한국정보과학회 학술발표논문집 Vol.31 No.1A
본 논문은 블루투스 피코넷을 이용하여 임베디드 시스템을 원격으로 제어하는 것을 목적으로 한다. 이를 위하여 범용 임베디드 시스템에 리눅스 커널을 포팅하고 근거리 무선 통신 규격인 블루투스 기술을 이용하여 산업장비 원격으로 제어하는 블루투스 피코넷 시스템을 설계한다. 각 임베디드 장비는 블루투스 피코넷을 이용하여 개별 제어뿐만 아니라 동시제어가 가능하도록 하였다. 이것은 임베디드 웹 서버를 통해 현장뿐만 아니라 어디에서든지 원격 제어가 가능하다.
반복 연산 스트레스의 레벨 인식 시스템 구성에 관한 연구
박광훈 ( Gwang Hoon Park ),김승태 ( Seung Tae Kim ),이윤진 ( Youn Jin Lee ),장중식 ( Jung Sik Chang ),고한우 ( Han Woo Ko ),김동선 ( Dong Sun Kim ),신동규 ( Dong Kyu Shin ) 한국감성과학회 1999 추계학술대회 Vol.1999 No.-
본 연구에서는 20대 남자 대학생 45명에게 세단계의 난이도를 갖는 덧셈연산을 수행하게 하여 반복 연산 스트레스를 유발시켰고, 각각의 피검자들로부터 생체신호를 측정하였다. 측정된 생체신호로부터 8개의 감성 파라메터를 추출하였다. 연산스트레스의 감성지수화를 위하여 세단계의 감성지수 인식 시스템을 구성하였으며 각 단계의 감성지수 판별을 위하여 선형 판별 알고리즘을 이용하였다. 판별성능 분석은 Cross Validation 을 통하여 수행하였으며 연산스트레스의 감성지수 인식율은, 학습용 데이타에서는 77.66% Cross Validation 에서는 63.02%의 일반화된 감성지수 인식성능을 보였다.
( Hyun Sun Yun ),( Ju Hee Heo ),( Seok Jun Son ),( Mi Ri Park ),( Sang Nam Oh ),( Min Ho Song ),( Jong Nam Kim ),( Gwang Woong Go ),( Ho Seong Cho ),( Nag Jin Choi ),( Seung Wha Jo ),( Do Youn Jeong ) 한국미생물 · 생명공학회 2014 Journal of microbiology and biotechnology Vol.24 No.8
We investigated whether Bacillus spp., newly isolated from Korean traditional food resources, influence the resistance of hosts to foodborne pathogens, by using Caenorhabditis elegans as a surrogate host model. Initially, we selected 20 Bacillus spp. that possess antimicrobial activity against various foodborne pathogens, including Staphylococcus aureus. Among the selected strains, six strains of Bacillus spp. used in preconditioning significantly prolonged the survival of nematodes exposed to S. aureus. Based on 16S rRNA gene sequencing, all six strains were identified as B. licheniformis. Our findings suggest that preconditioning with B. licheniformis may modulate the host defense response against S. aureus.
만성 C형간염 환자에서 인터페론 알파와 리바비린 병합요법의 치료 효과와 합병증
황상연 ( Sang Youn Hwang ),이혜정 ( Hae Jung Lee ),박기태 ( Kee Tae Park ),김경엽 ( Kyung Yup Kim ),이선미 ( Sun Mi Lee ),박찬원 ( Chan Won Park ),김태오 ( Tae Oh Kim ),김광하 ( Gwang Ha Kim ),허정 ( Jeong Heo ),강대환 ( Dae Hwan 대한소화기학회 2007 대한소화기학회지 Vol.49 No.3
목적: 만성 C형간염 환자의 인터페론 혹은 페그인터페론과 리바비린 병합요법의 치료 효과는 잘 알려져 있다. 그러나 치료에 따른 합병증을 중점으로 다룬 연구는 많지 않다. 이번 연구는 다양한 범주의 만성 C형간염 환자를 대상으로 인터페론과 리바비린 병합요법의 효용성과 합병증을 연구하고자 하였다. 대상 및 방법: 2001년 1월부터 2005년 1월까지 부산대학교병원에서 인터페론과 리바비린을 투여 받은 240명의 만성 C형간염 환자를 대상으로 치료 합병증을 평가하였고, 그중 치료를 종결한 154명의 환자를 대상으로 이들의 치료종결반응(end of treatment resoponse, ETR)과 지속바이러스반응(sustained virologic response, SVR)을 후향으로 평가하였다. 투여기간은 유전자 1형은 12개월, 비 1형은 6개월로 하였고, 인터페론 알파 300만 단위를 주 3회 피하주사로, 리바비린 800-1,200 mg을 매일 경구로 투여하였다. 결과: 총 240명의 환자의 남녀비는 143:97였고, 유전자 1형은 111명, 비 1형은 106명, 검사하지 않았거나 분석할 수 없었던 경우가 23명이었다. 치료를 완료한 154명의 ETR, SVR은 각각 79.2%, 61.0%였고, ETR을 보인 환자 중 SVR에 관한 추적관찰을 하지 못한 13명을 제외하였을 때 SVR은 66.7%였다. 치료를 조기에 중단한 환자는 35.8%로 순수 치료 부작용으로 인한 경우가 15.4%, 추적방문 실패로 인한 경우가 7.9%, 치료 경과 중 바이러스 음전실패 및 돌파현상으로 인한 경우가 11.3%, 그 외 원발 복막염, 간세포암종, 심근경색의 경우가 1.2%였다. 부작용으로 치료를 중단했던 경우는 간기능 악화가 8명, 우울증과 관련된 증상이 10명 (식욕부진 5명, 무력감 및 피곤함 2명, 자살충동 2명, 불면증 1명), 체질증상이 7명, 탈모 4명, 피부발진 2명, 혈소판 감소 2명, 그 외 피부 소양증, 설사, 흉통, 체중 감소가 각각 1명이었다. 빈혈로 인해 리바비린을 감량한 경우는 37명(15.4%), 백혈구 감소와 혈소판 감소로 인터페론을 감량한 경우는 각각 21명(8.8%)과 11명(4.6%)이었다. 결론: 치료를 완료한 환자들의 SVR은 61.0%였고, 환자의 약 3분의 1이 치료반응 부족, 부작용 및 순응도 부족으로 치료를 조기 중단하였다. Background/Aims: The effectiveness of combination therapy with conventional or pegylated interferon alpha and ribavirin in patients with chronic hepatitis C is well understood. However, the profound investigation about complications of the treatment has been rarely reported in Korea, where patients have broader spectrum of disease manifestations. The aim of this study was to evaluate the effectiveness and complications of the combination therapy of interferon alpha and ribavirin in patients with chronic hepatitis C. Methods: Two hundred and forty patients with chronic hepatitis C were included. All patients were treated with interferon alpha (3 million units thrice a week) in combination with ribavirin (800-1,200 mg, depending on body weight). Patients were treated for 6 or 12 months according to the genotypes (genotype 1; 12 months, non-1; 6 months). We retrospectively evaluated ETR (end of treatment response) and SVR (sustained virologic response) on the basis of intent-to-treat in patients completing the therapy. Results: In 154 patients who had completed the therapy, ETR was 79.2% and SVR was 61.0%. Multivariate analysis showed that genotype and early virologic response at 3 months of treatment were indepedent predictive factors of SVR. Due to insufficient response, 11.3% of the patients discontinued the therapy. In addition, 24.5% of the patients prematurely discontinued the therapy due to adverse events including aggravated liver function (15.4%), failure to return (7.9%), and others (1.2%). Dose modifications of interferon alpha or ribavirin were required due to anemia (15.4%), neutropenia (8.8%), or thrombocytopenia (4.6%). Conclusions: The overall SVR of patients who had completed the combination therapy with interferon alpha and ribavirin was 61.0%. However, about one third of the patients discontinued the therapy prematurely due to insufficient response, adverse events and/or noncompliance. (Korean J Gastroenterol 2007;49:166-172)
Kyung-Ah Kim,Gwang Hyun Choi,Eun Sun Jang,Young Seok Kim,Youn Jae Lee,In Hee Kim,Sung Bum Cho,Moran Ki,Hwa Young Choi,Dahye Paik,Sook-Hyang Jeong 한국역학회 2021 Epidemiology and Health Vol.43 No.-
OBJECTIVES: Injection drug use is a major risk factor for hepatitis C virus (HCV) infection; however, limited data on this topic are available in Korea. Thus, this study aimed to investigate the epidemiological and clinical characteristics, treatment uptake, and outcomes of HCV infection among people who inject drugs (PWID). METHODS: We used the data from the Korea HCV cohort, which prospectively enrolled patients with HCV infection between 2007 and 2019. Clinical data and results of a questionnaire survey on lifetime risk factors for HCV infection were analyzed according to a self-reported history of injection drug use (PWID vs. non-PWID group). RESULTS: Among the 2,468 patients, 166 (6.7%) were in the PWID group, which contained younger patients (50.6±8.2 vs. 58.2±13.1 years) and a higher proportion of male (81.9 vs. 48.8%) than the non-PWID group. The distribution of PWID showed significant regional variations. Exposure to other risk factors for HCV infection was different between the groups. The proportion of patients with genotype non-2 infection was higher in the PWID group. Treatment uptake was higher in the PWID group in the interferon era; however, it was comparable between the groups in the direct-acting antiviral era. The rate of sustained virological response did not significantly differ between the groups. CONCLUSIONS: As of 2019, PWID constituted a minority of HCV-infected people in Korea. The epidemiological characteristics, but not treatment uptake and outcomes, were different between the PWID and non-PWID groups. Therefore, active HCV screening and treatment should be offered to PWID in Korea.